NCT05286710 Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb
| NCT ID | NCT05286710 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Deep Vein Thrombosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2022-09-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ipsilateral popliteal venous the most common access for pharmacomechanical thrombectomy (PMT) in the treatment of acute deep venous thrombosis (DVT), but the result was not satisfactory. The investigators adjust the access to improve the thrombus clearance rate and reduce the incidence of post-thrombotic syndrome (PTS).
Eligibility Criteria
Inclusion Criteria: * Age between 18-80 years old; * Acute DVT with clinical symptoms occurred less than 14 days since the onset of disease; * DVT with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and/or calf vein; * Informed consent signed by patients. Exclusion Criteria: * Patients with the previous history of the same side of lower-limb DVT; * Patients with plasma Creatinine level greater than 180umol/L; * Patients who are contraindicated to thrombolysis; * Patients with inferior vena cava thrombosis; * Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent; * Patients who have participated in a clinical trial in the past three months; * Women during pregnancy and lactation * Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<2 years); * Patients with autoimmune thrombopathy or thrombocytopenia (platelets \< 80·10⁹/L); * Patients who are unable or unwilling to participate in the study.
Contact & Investigator
Meng Ye, M.D.
STUDY DIRECTOR
Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University
Frequently Asked Questions
Who can join the NCT05286710 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Deep Vein Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05286710 currently recruiting?
Yes, NCT05286710 is actively recruiting participants. Contact the research team at niqihong1989@163.com for enrollment information.
Where is the NCT05286710 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05286710 clinical trial?
NCT05286710 is sponsored by RenJi Hospital. The principal investigator is Meng Ye, M.D. at Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University. The trial plans to enroll 160 participants.